Targeted-release budesonide therapy for IgA nephropathy

Targeted-release budesonide therapy for IgA nephropathy

Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2017-12, Vol.390 (10113), p.2625-2625
Hauptverfasser: Tsuda, Kenji, Tanimoto, Tetsuya, Mori, Jinichi, Kosugi, Kazuhiro, Komatsu, Tsunehiko
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
Immunoglobulins
Kidney diseases
Steroids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2625
container_issue 10113
container_start_page 2625
container_title The Lancet (British edition)
container_volume 390
creator Tsuda, Kenji
Tanimoto, Tetsuya
Mori, Jinichi
Kosugi, Kazuhiro
Komatsu, Tsunehiko
description Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1·0 g/day, as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3
doi_str_mv 10.1016/S0140-6736(17)32145-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1978733932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673617321451</els_id><sourcerecordid>1978733932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-26cad4782ffa20d0cd8509feab7b5b44ea6931bdbc26c0e1f5199ffd76727dcf3</originalsourceid><addsrcrecordid>eNqF0E1LwzAYwPEgipvTj6AUvMxDNWmSZj3JGL4MBh6c4C2kyZOto2tq0gr79nYv7uDFUy6_53nCH6Frgu8JJunDOyYMx6mg6ZCIO5oQxmNygvqECRZzJj5PUf9IeugihBXGmKWYn6NekiU8ZZj2kZgrv4AGTOyhBBUgylsDwVWFgahZglf1JrLOR9PFOKqgXnpXq2a5uURnVpUBrg7vAH08P80nr_Hs7WU6Gc9izRhu4iTVyjAxSqxVCTZYmxHHmQWVi5znjIFKM0pyk-tOYiCWkyyz1ohUJMJoSwdouN9be_fVQmjkuggaylJV4NogSSZGgtKMJh29_UNXrvVV97tOjSjjjDDWKb5X2rsQPFhZ-2Kt_EYSLLdl5a6s3GaTRMhdWUm6uZvD9jZfgzlO_abswOMeQJfjuwAvgy6g0mAKD7qRxhX_nPgBejKHfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983454144</pqid></control><display><type>article</type><title>Targeted-release budesonide therapy for IgA nephropathy</title><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Tsuda, Kenji ; Tanimoto, Tetsuya ; Mori, Jinichi ; Kosugi, Kazuhiro ; Komatsu, Tsunehiko</creator><creatorcontrib>Tsuda, Kenji ; Tanimoto, Tetsuya ; Mori, Jinichi ; Kosugi, Kazuhiro ; Komatsu, Tsunehiko</creatorcontrib><description>Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1·0 g/day, as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(17)32145-1</identifier><identifier>PMID: 29256403</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Drug therapy ; Immunoglobulins ; Kidney diseases ; Steroids</subject><ispartof>The Lancet (British edition), 2017-12, Vol.390 (10113), p.2625-2625</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Dec 16, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-26cad4782ffa20d0cd8509feab7b5b44ea6931bdbc26c0e1f5199ffd76727dcf3</citedby><cites>FETCH-LOGICAL-c440t-26cad4782ffa20d0cd8509feab7b5b44ea6931bdbc26c0e1f5199ffd76727dcf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1983454144?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29256403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsuda, Kenji</creatorcontrib><creatorcontrib>Tanimoto, Tetsuya</creatorcontrib><creatorcontrib>Mori, Jinichi</creatorcontrib><creatorcontrib>Kosugi, Kazuhiro</creatorcontrib><creatorcontrib>Komatsu, Tsunehiko</creatorcontrib><title>Targeted-release budesonide therapy for IgA nephropathy</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1·0 g/day, as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3</description><subject>Drug therapy</subject><subject>Immunoglobulins</subject><subject>Kidney diseases</subject><subject>Steroids</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0E1LwzAYwPEgipvTj6AUvMxDNWmSZj3JGL4MBh6c4C2kyZOto2tq0gr79nYv7uDFUy6_53nCH6Frgu8JJunDOyYMx6mg6ZCIO5oQxmNygvqECRZzJj5PUf9IeugihBXGmKWYn6NekiU8ZZj2kZgrv4AGTOyhBBUgylsDwVWFgahZglf1JrLOR9PFOKqgXnpXq2a5uURnVpUBrg7vAH08P80nr_Hs7WU6Gc9izRhu4iTVyjAxSqxVCTZYmxHHmQWVi5znjIFKM0pyk-tOYiCWkyyz1ohUJMJoSwdouN9be_fVQmjkuggaylJV4NogSSZGgtKMJh29_UNXrvVV97tOjSjjjDDWKb5X2rsQPFhZ-2Kt_EYSLLdl5a6s3GaTRMhdWUm6uZvD9jZfgzlO_abswOMeQJfjuwAvgy6g0mAKD7qRxhX_nPgBejKHfg</recordid><startdate>20171216</startdate><enddate>20171216</enddate><creator>Tsuda, Kenji</creator><creator>Tanimoto, Tetsuya</creator><creator>Mori, Jinichi</creator><creator>Kosugi, Kazuhiro</creator><creator>Komatsu, Tsunehiko</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20171216</creationdate><title>Targeted-release budesonide therapy for IgA nephropathy</title><author>Tsuda, Kenji ; Tanimoto, Tetsuya ; Mori, Jinichi ; Kosugi, Kazuhiro ; Komatsu, Tsunehiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-26cad4782ffa20d0cd8509feab7b5b44ea6931bdbc26c0e1f5199ffd76727dcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Drug therapy</topic><topic>Immunoglobulins</topic><topic>Kidney diseases</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuda, Kenji</creatorcontrib><creatorcontrib>Tanimoto, Tetsuya</creatorcontrib><creatorcontrib>Mori, Jinichi</creatorcontrib><creatorcontrib>Kosugi, Kazuhiro</creatorcontrib><creatorcontrib>Komatsu, Tsunehiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuda, Kenji</au><au>Tanimoto, Tetsuya</au><au>Mori, Jinichi</au><au>Kosugi, Kazuhiro</au><au>Komatsu, Tsunehiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted-release budesonide therapy for IgA nephropathy</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2017-12-16</date><risdate>2017</risdate><volume>390</volume><issue>10113</issue><spage>2625</spage><epage>2625</epage><pages>2625-2625</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1·0 g/day, as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29256403</pmid><doi>10.1016/S0140-6736(17)32145-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2017-12, Vol.390 (10113), p.2625-2625
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_1978733932
source Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland
subjects Drug therapy
Immunoglobulins
Kidney diseases
Steroids
title Targeted-release budesonide therapy for IgA nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A06%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted-release%20budesonide%20therapy%20for%20IgA%20nephropathy&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Tsuda,%20Kenji&rft.date=2017-12-16&rft.volume=390&rft.issue=10113&rft.spage=2625&rft.epage=2625&rft.pages=2625-2625&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(17)32145-1&rft_dat=%3Cproquest_cross%3E1978733932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983454144&rft_id=info:pmid/29256403&rft_els_id=S0140673617321451&rfr_iscdi=true